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ABSTRACT
Murine embryonic stem (ES) cells can differentiate in vitro into three germ layers 
(endodermic, mesodermic, ectodermic). Studies on the differentiation of these cells 
to specific early differentiation stages has been aided by an ES cell line carrying 
the Green Fluorescent Protein (GFP) targeted to the Brachyury (Bry) locus which 
marks mesoderm commitment. Furthermore, expression of the Vascular Endothelial 
Growth Factor receptor 2 (Flk1) along with Bry defines hemangioblast commitment. 
Isobaric-tag for relative and absolute quantification (iTRAQTM) and phosphopeptide 
enrichment coupled to liquid chromatography separation and mass spectrometry 
allow the study of phosphorylation changes occurring at different stages of ES cell 
development using Bry and Flk1 expression respectively. We identified and relatively 
quantified 37 phosphoentities which are modulated during mesoderm-induced ES 
cells differentiation, comparing epiblast-like, early mesoderm and hemangioblast-
enriched cells. Among the proteins differentially phosphorylated toward mesoderm 
differentiation were: the epigenetic regulator Dnmt3b, the protein kinase GSK3b, 
the chromatin remodeling factor Smarcc1, the transcription factor Utf1; as well as 
protein specifically related to stem cell differentiation, as Eomes, Hmga2, Ints1 and 
Rif1. As most key factors regulating early hematopoietic development have also 
been implicated in various types of leukemia, understanding the post-translational 
modifications driving their regulation during normal development could result in a 
better comprehension of their roles during abnormal hematopoiesis in leukemia.
INTRODUCTION
Mouse embryonic stem cells (mESCs) are the 
in vitro counterparts of an in vivo population of cells 
specific to the early embryo within the inner cell mass. ES 
cells are pluripotent and different culture conditions can 
induce them to differentiate into the three primary germ 
layers (mesoderm, ectoderm and endoderm). In the mouse 
embryo around 6.5 days of gestation, epiblast cells migrate 
to form the primitive streak which contains the nascent 
mesoderm. Derived from mesoderm, hematopoiesis 
occurs in a consequent temporal pattern during embryonic 
development, around 7.5 days gestation in the blood 
islands in the yolk sac. Associated with this process is the 
formation of the hemangioblast population. This transient 
progenitor cell with the capacity to give rise to both 
endothelial and hematopoietic progenitors has been shown 
to be formed within the primitive streak [1].
mESCs have been studied extensively since they 
represent a potentially vast source of cells and tissues 
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for regenerative medicine. Although there are data on 
the molecular processes governing the formation of 
hemangioblasts [2], specific phosphorylation events within 
the nucleus governing development have not yet been 
systematically analysed, and the mechanistic detail on 
how the hemangioblast is formed requires further analysis.
To further delineate the hemangioblast population, 
a reporter ES cell line with the GFP coding sequences 
targeted into the Brachyury (Bry) locus was created by 
Fehling et al [3]. ES cells can differentiate in vitro to 
form spheroid cultures called embryonic bodies (EBs). 
These structures contain the derivatives of all the three 
germ layers, and it is possible to track mesoderm and 
hematopoietic lineage commitment in vitro with the 
temporal expression of two specific genes, restricted to 
the lineage of interest. Bry, a member of the T-box gene 
family, is a marker for the early mesoderm formation 
(the majority of the cells in the primitive streak are Bry 
positive). Bry expression decreases when cells migrate 
away from the primitive streak and further differentiate. 
Flk1, the vascular endothelial growth factor receptor 
2, identifies a mesodermal population of cells further 
committed for differentiation and is commonly expressed 
with Bry in populations with hematopoietic potential. 
The analysis of Bry and Flk1 expression allowed for the 
detection of three subpopulations: the Bry-Flk1- population 
represents mES cells that have not yet undergone the 
differentiation process, thus resembling epiblast cells. The 
Bry+Flk1– fraction corresponds to a population of early 
mesoderm differentiating cells. The Bry+Flk1+ fraction 
contains precursors for endothelial and hematopoietic 
lineages, the blast-colony forming cells (BL-CFC), 
representing the in vitro equivalent of the hemangioblast.
We have previously reported changes occurring in 
mES cells nuclear proteome during mesoderm-induced 
differentiation, using isobaric tags for relative and absolute 
quantification (iTRAQTM) coupled to LC-MS/MS analysis 
[4]. This approach allowed a relatively deep proteomic 
penetration. However, activities of proteins are often 
regulated by translation and degradation rates, as well as 
by post-translational modifications, e.g. phosphorylation. 
It has been recently reported that post-translational 
modifications occur during ES cells differentiation, and 
they are also required for ES cell self-renewal [5]. Protein 
phosphorylation has been demonstrated to be involved 
in the regulation of many aspects of cellular functions 
including cell proliferation, differentiation, migration and 
signal transduction. It is likely that extracellular signals 
in part convey their signals to the nucleus to engender 
epigenetic changes to initiate altered gene transcription 
[6]. In the process of mesoderm formation some signaling 
molecules have defined roles in proliferation and 
development control, such as tumor growth factor beta, 
FGF, Wnt and Hedgehog families; in mouse, BMP4, Wnt3 
or Nodal, are essential for mesoderm development [7–8]. 
Mice lacking canonical Wnt ligands do not develop the 
primitive streak and fail to generate mesoderm from the 
epiblast [9–11]. Therefore the Wnt signaling pathway is 
involved in the mechanism that induces mouse ES cells to 
differentiate, switching from self-renewal to differentiation. 
Phosphorylation mapping, by means of proteomic 
technologies, serves as a starting point for establishing a 
comprehensive database of the stem cell phosphoproteome. 
To define the phosphoproteome of hemangioblast cells, we 
compared it with that of epiblast-like and early mesoderm 
populations. Our observations provide potential new 
pathways for analysis of regulation in ES cell differentiation 
to the hemangioblast fate, that could also be unraveled in 
leukemias. Interestingly, recent findings propose a pivotal 
role for GSK3 and the chromatin remodeling factor 
Smarcc1/Baf155 in the decision fate of hematopoietic stem 
cells to differentiate. GSK3 is an important regulator of 
stem cell homeostasis, in particular ES cell self-renewal 
[12], but it also been recently implicated in leukemia stem 
cell physiology [13–14]. Smarcc1/Baf155 is necessary 
for heterochromatin formation and chromatin compaction 
during the differentiation process.
RESULTS
Phosphoproteomic analysis of early embryonic 
development
Once cultured without LIF and embryonic feeders, 
ES cells differentiate in vitro toward the mesoderm 
lineage. Three different populations, Bry-Flk1-, Bry+Flk1- 
and Bry+Flk1+, were isolated from the differentiating ES 
cell culture as previously described [3] (Figure 1A). 
These distinct populations have been seen to represent 
epiblast, mesoderm committed and blast like colony 
forming (BL-CFC) cells. Approximately 1 × 107 cells 
were collected for each population, nuclear enrichment 
was performed to concentrate the downstream proteomic 
analysis on pathways associated with regulation of 
gene expression (Figure S1). The same amount of each 
nuclear protein tryptic lysates (100 μg) was labeled with 
one of the 4-plex iTRAQTM channel reagents. All four 
reagents were used, allowing one internal control within 
the same LC-MS/MS experiment (Bry–Flk1– nuclear 
lysate was labeled with two different iTRAQTM reagents) 
(Figure 1B). The samples were combined and enrichment 
for phosphopeptides performed using the TiO
2
 metal 
affinity enrichment approach. Samples were fraction-
ated using SCX chromatography, before LC-MS/MS 
analysis. Data recorded from two independent biological 
replicates were analyzed using the Paragon Algorithm 
within the ProteinPilotTM v.3.0. The total number of 
phosphopeptides identified was 2506, present in the two 
biological replicates, with 20% of confidence (Table S1). 
The data acquired showed a normal distribution between 
biological replicates with a modal value centered around 
0 (1 in the linear scale) (Figure 1C).
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Relative quantification of phosphorylation changes 
occurring in the hemangioblast formation
Significance thresholds and quantitative phosphorylation 
changes were determined according to previous analysis 
[4–15–16]. To establish whether there was a change in peptide 
phosphorylation, only phosphopeptides exceeding 95% of the 
identifications compared to the control:control ratio (Bry–Flk1–: 
Bry–Flk1–) were considered. The interval of significance was 
calculated for each replicate based on the normal distribution 
of the internal control ratio (Figure 1C). Phosphorylation level 
was considered significantly changing when the fold change 
was < 0.6 (decrease) or > 1.5 (increase). Phosphopeptides 
with a ratio within the intervals of significance were manually 
removed from the data. Spectra were then manually checked 
to verify phosphorylation assignment, based on intact 
fragment presence, neutral loss of HPO
3
 (80 Da) or neutral 
loss of H
3
PO
4
 (98 Da). Using these stringent selection criteria 
37 phosphoentities were of interest as they change during 
ES cell differentiation (see Table 1). With the exception 
of Vars, the phosphopeptides have been also identified 
in other phosphoproteomic analyses [17–20]. For only 9 
phosphopeptides, the modification site and the protein kinase 
were determined using site-specific methods (referring to 
the phosphorylation site repository found on http://www.
phosphosite.org/: 178226 non-curated sites, 103952 sites 
curated from literature) (Table 2). Regarding those peptides 
included in Table 1, epiblast cells shown 7 phosphoentities 
up-regulated and 14 phosphoentities down-regulated; early 
mesoderm cells exhibited 6 phosphoentities up-regulated and 
Figure 1: . (A) Flow cytometric sorting of ES cells at specific time points of the hematopoietic differentiation for nuclear 
phosphoproteome analysis. Differentiating ES cells were enriched based on Bry and Flk1 expression. 2 × 107 cells were used for each 
experiment. At 2.5 days of differentiation, Bry-Flk1- cells, corresponding to the epiblast-like stage, were collected by flow cytometric 
sorting (1). At 3.5 days two other populations, Bry+Flk1- and Bry+Flk1+, corresponding to the mesoderm and hemangioblast (BL-CFC) cell 
populations, respectively, were collected (2). (B) Schematic workflow for the identification of changes in the phosphoproteome of mouse 
embryonic stem cells committed to the hematopoietic differentiation. Mouse embryonic stem cells sorted for Bry and Flk1 were generated 
from biological replicates. 100 μg of nuclear lysate were digested with trypsin to produce peptides that were labeled with 4-plex iTRAQTM 
reagent. Combined samples were then enriched for phosphopeptides via TiO
2
 column, separated with strong cation exchange chromatography 
(SCX) and subjected to nano-RPLC-MS/MS on a QTof mass spectrometer. (C) Distribution of the phosphoentity quantification ratios. Data 
normalization was obtained transforming all control ratios of phosphoentities identified with a sequence confidence above 20% with the 
logarithmic function at the base 2 (bins ranging from -2 to 2).
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Table 1: Phosphopeptides identified as changing in differentiating ES on analysis of iTRAQTM relative 
quantification. 
Acc.nb Gene 
name
Protein 
name
Phosphopeptide 
sequence
Bry+Flk-: 
Bry-Flk-
Bry+Flk+: 
Bry+Flk–
Bry+Flk+: 
Bry–Flk–
GO Biological 
Process
GO 
Molecular 
Function
P57776 Eef1d
eEF1d 
protein
GATPAEDDE 
DKDIDLFG 
pSDEEEEDKEAAR
1.5 1.09 1.61
Positive 
regulation of 
NF-kB cascade
Signal 
transducer 
activity; 
Translational 
elongation 
factor activity
P57776 Eef1d
eEF1d 
protein
ATAPQTQ 
HVpSPMR 1.96 0.77 1.48
Positive 
regulation of 
NF-kB cascade
Signal 
transducer 
activity; 
Translational 
elongation 
factor activity
Q6J1H4 Utf1 UTF1
RLPAFSPP 
SPApSPDAELR 0.36 0.5 0.17
Transcription, 
DNA-dependent
Transcription 
coactivator 
activity
Q6J1H4 Utf1 UTF1
RLPAFpSPPS 
PApSPDAELR 0.38 0.42 0.16
Transcription, 
DNA-dependent
Transcription 
coactivator 
activity
Q6J1H4 Utf1 UTF1
RLPAFSPP 
pSPASPDAELR 0.37 0.54 0.2
Transcription, 
DNA-dependent
Transcription 
coactivator 
activity
Q6J1H4 Utf1 UTF1
RLPAFSPP 
pSPApSPDAELR 0.31 0.58 0.18
Transcription, 
DNA-dependent
Transcription 
coactivator 
activity
Q6J1H4 Utf1 UTF1
SAGDVPVTTS 
DAFATSGGM 
AEPGpSPK
0.39 0.48 0.19
Transcription, 
DNA-dependent
Transcription 
coactivator 
activity
P17095 Hmga1
High mobility 
group protein 
HMG-I/HMG-Y
KQPPV 
pSPGTALVGSQK 1.22 0.59 0.73
Regulation of 
transcription; 
DNA-dependent, 
Negative 
regulation of cell 
proliferation
DNA-
binding; 
Transcription 
coactivator 
activity
P52927 Hmga2
High mobility 
group protein 
HMG-A2
KQQQEPTCEP 
pSPKRPR 1.29 1.89 2.38
Positive 
regulation 
of stem cell 
proliferation
A-T DNA 
binding
Q9CQS8 Sec61b Sec61 beta subunit
PGPTPSGTNVGS 
pSGRSPSK 1.07 1.61 1.71 Protein transport
Ribosome 
binding
Q9CQS8 Sec61b Sec61 beta subunit
PGPTPSGTNV 
GSSGRpSPSK 1.1 1.52 1.63 Protein transport
Ribosome 
binding
P30999 Ctnnd1
Catenin delta-1 
(p120 catenin)
GSLApSLDSLRK 0.78 0.62 0.48
Wnt receptor 
signaling 
pathway; 
Regulation of 
transcription, 
DNA-dependent
Protein 
phosphatase 
binding; 
Protein kinase 
binding
(Continued )
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Acc.nb Gene 
name
Protein 
name
Phosphopeptide 
sequence
Bry+Flk-: 
Bry-Flk-
Bry+Flk+: 
Bry+Flk–
Bry+Flk+: 
Bry–Flk–
GO Biological 
Process
GO 
Molecular 
Function
Q8K019 Bclaf1
Bcl-2-associated 
transcription factor IDIpSPSALRK 0.53 1.35 0.7
Regulation of 
transcription, 
DNA-dependent; 
Positive 
regulation of 
apoptosis
Protein 
binding; DNA 
binding
Q9WV60 Gsk3b
Glycogen 
synthase 
kinase 3b
GEPNVpSYICSR 0.15 1.48 1.67
Genetic 
imprinting; 
Multicellular 
organismal 
development; 
Wnt receptor 
signaling 
pathway
Protein kinase 
binding; 
Transferase 
activity
O88509 Dnmt3b
DNA 
(cytosine-5) 
methyltrans- 
ferase 3B
TTNDSAASE 
pSPPPKR 0.38 0.51 0.19
Methylation: 
Epigenetic
Transferase 
activity
Q01320 Top2a
Topoisomerase 
(DNA) II alpha
KPIKYLEE 
pSDDDDDLF 0.52 1.58 0.81
ATP catabolic 
process; Mitotic 
recombination; 
Embryonic 
cleavage
DNA 
topoisomerase 
activity; 
Chromatin 
binding
P14733 Lmnb1 Lamin B1 LKLpSPSPSSR 0.64 0.77 0.48
G2/M-specific 
positive 
regulation of 
cyclin-dependent 
protein kinase 
activity Positive 
regulation of 
JNK cascade
JUN kinase 
binding; 
Phospholipase 
binding
Q8BTI8 Srrm2
Serine/arginine 
repetitive matrix 2
MVQASSQSLLP 
PAQDRPRp 
SPVPSAFSDQSR
0.59 0.78 0.46
RNA splicing; 
mRNA 
processing
Protein 
N-terminus 
binding
Q569Z6 Thrap3
Thyroid hormone 
receptor 
associated protein 
3
RIDIpSPSTFR 0.56 1 0.55
Steroid hormone 
receptor 
signaling 
pathway; 
Transcription - 
DNA dependent
Transcription 
coactivator 
activity; 
Nucleotide 
binding
P97496 Smarcc1
SWI/SNF 
complex 155 kDa 
subunit
RKPpSP 
pSPPPPTATESR 1.6 0.75 1.2
Chromatin 
remodeling; 
Organ 
morphogenesis; 
Transcription, 
DNA-dependent
Protein 
binding; 
DNA binding
Q8VDF2 Uhrf1
E3 ubiquitin-
protein ligase 
UHRF1
RPLIA 
pSPSQPPPALR 0.82 0.7 0.56
Cell 
proliferation; 
Regulation of 
transcription, 
DNA-
dependent; 
Multicellular 
organismal 
development
DNA 
binding; 
Methyl-CpG 
binding
(Continued )
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Acc.nb Gene 
name
Protein 
name
Phosphopeptide 
sequence
Bry+Flk-: 
Bry-Flk-
Bry+Flk+: 
Bry+Flk–
Bry+Flk+: 
Bry–Flk–
GO Biological 
Process
GO 
Molecular 
Function
P60904 Dnajc5
DnaJ (Hsp40) 
homolog, 
subfamily C, 
member 5
SLpSTSGESL 
YHVLGLDK
1.35 1.11 1.51
Protein folding; 
Negative 
regulation 
of neuron 
apoptosis
ATP-
dependent 
protein 
binding; Heat 
shock protein 
binding; 
Unfolded 
protein 
binding
Q8K310 Matr3 Matrin-3
TEpSPAE 
GKEQEEK
0.49 1.16 0.58 Unannotated
Nucleic acid 
binding
Q9Z1Q9 Vars Valyl-tRNA synthetase
LpSATVTEAF 
VRLHEEGVI
1.44 0.56 0.79
tRNA 
aminoacylation 
for protein 
translation
Aminoacyl-
tRNA ligase 
activity; 
Nucleotide 
binding
Q80XU3 Nucks1
Nuclear 
ubiquitous casein 
and cdk substrate
ATVTP 
pSPVKGK 0.56 0.85 0.47 Unannotated DNA binding
Q6PR54 Rif1
Rap1-interacting 
factor 1
SSDpSVD 
IEEQEEK
0.69 0.58 0.37
Stem cell 
maintenance; 
cell cycle; 
Response to 
DNA damage 
stimulus
Protein 
binding
Q6PR54 Rif1
Rap1-interacting 
factor 1
VSDSSL 
pSPEK 0.84 0.64 0.53
Stem cell 
maintenance; cell 
cycle; Response 
to DNA damage 
stimulus
Protein 
binding
Q8CBW3 Abi1 Abl interactor 1
TNPPTQKPP 
SPPVpSGR 0.99 1.67 1.64
Peptidyl-
tyrosine 
phosphorylation; 
Cell motility
Protein 
binding; 
Protein 
tyrosine 
kinase 
activator 
activity
Q08943 Ssrp1
FACT complex 
subunit SSRP1
EGINPGYD 
DYADpSDE 
DQHDAYLER
1.56 0.68 1.05
Regulation of 
transcription, 
DNA-dependent
DNA binding
Q64012 Raly
hnRNP-associated 
with lethal yellow
GRLpSPVPVPR 2.53 0.47 1.37
RNA splicing; 
mRNA 
processing
RNA binding
Q9JIX8 Acin1 Acinus
HLpSHPEP 
EQQHVIQR
1.15 0.52 0.59
Apoptosis; 
Apoptotic 
chromosome 
condensation
Nucleic acid 
binding; 
Nucleotide 
binding
P11499
Hsp 
90ab1
Heat-shock 
protein hsp84
IEDVGpSDE 
EDDSGKDK
0.55 1.35 0.73
Protein folding; 
Response to 
stress; Placenta 
development
Protein 
binding
(Continued )
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12 phosphoentities down-regulated; in the hemangioblast 10 
phosphoentities were up-regulated and 16 phosphoentities 
down-regulated.
We focused the data analysis on early phosphorylative 
changes, occurring in the first stages of the differentiation 
process, proceeding from the epiblast to the early mesoderm 
cells (Bry+Flk1– and Bry–Flk1–), and those which are 
differentially regulated in the BL-CFC cells (Bry+Flk1+). 
According to this analysis, phosphopeptides can be divided 
into 3 groups. Group 1: phosphopeptides up- or down-
regulated during early mesoderm differentiation. Group 2: 
phosphopeptides up- or down-regulated in BL-CFC cells. 
Acc.nb Gene 
name
Protein 
name
Phosphopeptide 
sequence
Bry+Flk-: 
Bry-Flk-
Bry+Flk+: 
Bry+Flk–
Bry+Flk+: 
Bry–Flk–
GO Biological 
Process
GO 
Molecular 
Function
P42208 Sept2
Septin 2 (NEDD5 
protein)
IYHLPDAE 
pSDEDE 
DFKEQTR
1.01 1.68 1.69 Cell cycle
GTPase 
activity; 
Protein 
binding
O54839 Eomes Eomes
KGpSPC 
AEEELPS 
AATAAATAR
1.52 0.76 1.15
Blastocyst 
development; 
Multicellular 
organismal 
development; 
Stem cell 
maintenance; 
Mesoderm 
formation; 
Endoderm 
formation; 
Interferon-
gamma 
production
DNA 
binding; 
Transcription 
factor 
activity
Q9CW46 Raver1
Ribonucleoprotein 
PTB-binding 1
LLpSPIASNR 1.33 0.49 0.65 Unannotated RNA binding
Q6P4S8 Ints1
Integrator 
complex subunit 1
LSpSTP 
PLSALGR
2.45 0.66 1.62
snRNA 
processing; 
Blastocyst 
growth; Inner 
cell mass cell 
proliferation; 
Apoptosis
Unannotated
Q8CGU3 Pnn Pinin
RGFpSD 
SGGGPPAK
1.26 1.37 1.71
Cell-cell 
adhesion; 
Regulation of 
transcription, 
DNA-
dependent; RNA 
splicing; mRNA 
processing
DNA binding
To be considered as changing, a phosphopeptide should have a ratio outside the range in which 95% of phosphopeptides ratios 
for the internal control replicates are found. Phosphopeptides shown are those where a confident assessment of a significant 
decrease or increase was found. To be included the data must have a -fold change <0.6 or >1.5 with a p value of less than 
0.05. The significant changes are shown in bold; the underlined values represent changes where the confidence levels were 
not met. Every spectrum has been manually checked to verify phosphorylation. The first three columns report the Accession 
Number (UniProtKB-SwissProt), the Gene and Protein name, and the primary sequence of the phosphopeptide identified, 
indicating in bold the aminoacid modified by phosphorylation and in brackets the phosphosite position in the full length 
protein. The next three columns report the log(2) of the iTRAQ ratios representing the changes in phosphorylation level 
occurring during the progression of the hematopoietic differentiation, comparing Bry+Flk1–:Bry–Flk1–, Bry+Flk1+:Bry+Flk1- 
and Bry+Flk1+:Bry–Flk1–. The last two columns show the Biological process and Molecular function classification for 
the reported phosphopeptide-derived proteins, according to the Gene Ontology annotations. Data from two independent 
biological replicate were merged into the table.
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Table 2: Phosphosite retrieved informations based on mass spectrometry identification and 
esperimental evidences. 
Acc.nb Gene 
name
Protein name Phosphopeptide 
sequence
(P)site 
position
MS 
evidence
EX 
evidence
Protein 
kinase
P57776 Eef1d eEF1d protein
GATPAEDDED 
KDIDLFGpSD 
EEEEDKEAAR
S162 Y Y CK2
P57776 Eef1d eEF1d protein
ATAPQTQ 
HVpSPMR S133 Y Y Cdc2
Q6J1H4 Utf1 UTF1
RLPAFSPP 
SPApSPDAELR S18 Y N
Q6J1H4 Utf1 UTF1
RLPAFpSP 
PSPApSPDAELR S12, S18 Y N
Q6J1H4 Utf1 UTF1
RLPAFSPP 
pSPASPDAELR S15 Y N
Q6J1H4 Utf1 UTF1
RLPAFSPP 
pSPApSPDAELR S15, S18 Y N
Q6J1H4 Utf1 UTF1
SAGDVPVT 
TSDAFATS 
GGMAEPGpSPK
S48 Y N
P17095 Hmga1
High mobility group 
protein HMG-I/
HMG-Y
KQPPV 
pSPGTALVGSQK S36 Y Y
CDK2, 
HIPK2
P52927 Hmga2
High mobility group 
protein HMG-A2
KQQQEPT 
CEPpSPKRPR S44 Y Y Cdc2
Q9CQS8 Sec61b Sec61 beta subunit
PGPTPSGTN 
VGSpSGRSPSK S14 Y N
Q9CQS8 Sec61b Sec61 beta subunit
PGPTPSGTN 
VGSSGRpSPSK S17 Y N
P30999 Ctnnd1
Catenin delta-1 (p120 
catenin) GSLApSLDSLRK S346 Y N
Q8K019 Bclaf1
Bcl-2-associated 
transcription factor IDIpSPSALRK S656 Y N
Q9WV60 Gsk3b
Glycogen synthase 
kinase 3b
GEPNVpSYICSR S215 Y N
O88509 Dnmt3b
DNA (cytosine-5) 
methyltransferase 3B
TTNDSAASE 
pSPPPKR S399 Y N
Q01320 Top2a
Topoisomerase 
(DNA) II alpha
KPIKYLEE 
pSDDDDDLF S1521 Y Y
PLK1, 
CK2
P14733 Lmnb1 Lamin B1 LKLpSPSPSSR S392 Y N
Q8BTI8 Srrm2
Serine/arginine 
repetitive matrix 2
MVQASSQSLLP 
PAQDRPRpSP 
VPSAFSDQSR
S2404 Y N
Q569Z6 Thrap3
Thyroid hormone 
receptor associated 
protein 3
RIDIpSPSTFR S679 Y N
P97496 Smarcc1
SWI/SNF complex 
155 kDa subunit
RKPpSPpSP 
PPPTATESR
S327, S329 Y N
(Continued)
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Group 3: phosphopeptides changing neither in Bry-Flk1-, 
Bry+Flk1– nor Bry+Flk1+. Interestingly, almost half of the 
phosphopeptides that were differentially regulated in the 
Bry+Flk1– and Bry–Flk1–, were not changing in the Bry+Flk1+ 
and vice versa. Only phosphopeptides emanated from Ef1d 
and Ints1 were up-regulated either in the progression from 
Bry–Flk1– to Bry+Flk1– and in the Bry+Flk1+; Utf1, Dnmt3b, 
Srrm2 Thrap3, Matr3 and Nucks1 phosphopeptides were 
instead down-regulated in both stages. Only phosphopeptides 
belonging to the proteins Hmga1, Vars and Raver1 
Acc.nb Gene 
name
Protein name Phosphopeptide 
sequence
(P)site 
position
MS 
evidence
EX 
evidence
Protein 
kinase
Q8VDF2 Uhrf1
E3 ubiquitin-protein 
ligase UHRF1
RPLIApSPS 
QPPPALR
S289 Y N
P60904 Dnajc5
DnaJ (Hsp40) 
homolog, subfamily 
C, member 5
SLpSTSGES 
LYHVLGLDK
S10 Y Y AKT
Q8K310 Matr3 Matrin-3 TEpSPAEGKEQEEK S619 Y N
Q9Z1Q9 Vars Valyl-tRNA synthetase
LpSATVTEA 
FVRLHEEGVI
N.R. N N
Q80XU3 Nucks1
Nuclear ubiquitous 
casein and cdk 
substrate
ATVTPpSPVKGK S181 Y Y CDK2
Q6PR54 Rif1
Rap1-interacting 
factor 1
SSDpSVDIEEQEEK S1565 Y N
Q6PR54 Rif1
Rap1-interacting 
factor 1
VSDSSLpSPEK S1683 Y N
Q8CBW3 Abi1 Abl interactor 1
TNPPTQKPP 
SPPVpSGR S187 Y N
Q08943 Ssrp1
FACT complex 
subunit SSRP1
EGINPGYDD 
YADpSDED 
QHDAYLER
S444 Y N
Q64012 Raly
hnRNP-associated 
with lethal yellow
GRLpSPVPVPR S135 Y Y CDK2
Q9JIX8 Acin1 Acinus HLpSHPEPEQQHVIQR S710 Y N
P11499 Hsp90ab1
Heat-shock protein 
hsp84
IEDVG 
pSDEEDDSGKDK S255 Y Y
TK, 
CK2
P42208 Sept2
Septin 2 (NEDD5 
protein)
IYHLPDAE 
pSDEDEDFKEQTR S218 Y Y
O54839 Eomes Eomes KGpSPCAEE 
ELPSAATAAATAR
S117 Y N
Q9CW46 Raver1
Ribonucleoprotein 
PTB-binding 1
LLpSPIASNR S576 Y N
Q6P4S8 Ints1
Integrator complex 
subunit 1
LSpSTPPLSALGR S82 Y N
Q8CGU3 Pnn Pinin RGFpSDSGGGPPAK S66 Y N
The first three columns report the Accession Number (UniProtKB-SwissProt), the Gene and Protein name, and the primary 
sequence of the phosphopeptide identified, indicating in bold the aminoacid modified by phosphorylation and in brackets 
the phosphosite position in the full length protein. The next three columns report the phosphosite position with respect to 
the protein primary sequence, whether the site has been identified by mass-spectrometry based methods (MS evidence) and 
experimental methods (EX evidence). Y=yes, N=no. These informations were retrieved from PhosphositePlus; experimental 
methods include aminoacid sequencing, site-directed mutagenesis, modification site-specific antibodies and targeted MS 
strategies. The last column report the protein kinase responsible for the specific site phosphorylation, identified by EX 
evidences.
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were neither changing in the progression Bry–Flk1– to 
Bry+Flk1– and in the hemangioblast cells, indicating that 
post-translational regulation involving these proteins may 
be fundamental for the transition from the Bry+Flk1– to 
Bry+Flk1+.
The regulation of consequential temporal 
processes, by means of phosphorylation, 
governed the hemangioblast development
Comparing the phosphopeptides changing in 
Bry+Flk1+ and those which occur in the very early steps of 
differentiation, according to the Gene Ontology, different 
categories of biological processes were involved (Figure 2). 
Proteins involved in regulation of cell differentiation and 
gene expression, developmental processes and especially 
embryonic development, such as Ints1, Top2a, Dnmt3b and 
Gsk3b, Utf1, Bclaf1, Thrap3 and Ssrp1, were found to be 
differentially phosphorylated in all the three stages of ES 
cells differentiation (Figure 2A and 2C). Phosphorylation 
on Ints1 and Dnmt3b was regulated the same in Bry+Flk1–
:Bry–Flk1– and Bry+Flk1+:Bry–Flk1–; Top2a decreased in 
Bry+Flk1–:Bry–Flk1–, but it didn’t change in the Bry+Flk1+ 
while Gsk3b phosphorylation decreased as cells started to 
differentiate, then progressively increased as cells became 
Bry+Flk1+.
However, as expected, there are processing taking 
place in a consequential temporal pattern. As mES cells 
started to differentiate, phosphopeptides significantly 
changing were emanated from proteins involved in 
blastocyst and placenta development, the formation of 
the primary germ layer and mesoderm; such as Eomes, 
Hsp90ab1, Smarcc1 and Gsk3b. Conversely, as the BL-
CFC cells were formed, differentially phosphorylated 
peptides emanated from proteins involved in cell cycle, 
cell division and mRNA processing such as Uhrf1, 
Sept2, Rif1, Hmga2, Srrm2 and Pnn; in the regulation 
of phosphorylation and kinase activity, such as the Wnt 
Figure 2: Biological classification of differentially regulated phosphopeptides.. Pie chart representation of the phosphopeptide-
emanated proteins classified into groups by Biological process. Phosphopeptides from Group 1 (up- or down-regulated in Bry–Flk1– and 
Bry+Flk1–) and Group 2 (up- or down-regulated in Bry+Flk1+) were considered as they are indicative for the regulation of stem cell 
differentiation. The relative frequency of over-represented categories is reported as percentage in the pie charts. (A) and (C) Biological 
processes of phosphopeptides differentially regulated both in Group 1 and Group 2, respectively. (B) and (D) Biological processes specific 
to phosphopeptides differentially regulated either in Group 1 or Group 2. Gene Ontology classification was performed using the plugin 
BiNGO v2.42 within Cytoscape v.2.8.2, assessing over-represented categories with a hypergeometric statistical test and Benjamini & 
Hochberg False Discovery Rate correction (p < 0.05). As a reference set, the whole mouse repository annotation was used.
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receptor signaling pathway (Ctnnd1 and Abi1) and the 
JAK-STAT cascade (Hmga2). Notably, few proteins also 
had a role in cell-cell adhesion and cell motility, such as 
Ctnnd1, Pnn and Rif1.
Comparison with expression dataset
Twenty-one phosphopeptides within this dataset 
were found to emanate from proteins analyzed in the 
nuclear proteome expression analysis associated with Bry 
and Flk1 expression previously published [4] (Figure 3). 
Although the expression of the proteins did not change 
during hematopoietic differentiation, 9 phosphopeptides 
displayed differential regulation: Hmga1, Sec61b, Ctnnd1, 
Gsk3b, Dnajc5, Nucks1, Rif1, Ssrp1, Raver1. Among 
these, phosphorylation on Hmga1 and Raver1 only 
decreased in the progression from Bry+Flk1– to Bry+Flk1+; 
while Raver1 is involved in the regulation of alternative 
splicing [21], Hmga1 plays a role in modulation of gene 
expression during development and embryogenesis, 
and its expression is known to be markedly diminished 
in differentiated cells [22]. Interestingly, Ctnnd1, Gsk3 
and Rif1, are involved either in the regulation of cell 
differentiation and developmental processes, but also 
in the regulation of the cellular response to signaling 
pathways, such as the Wnt receptor signaling pathway. 
Moreover, GSK3 was found to play a pivotal role in 
controlling the decision fate of ES cells between self-
renewal and differentiation; in fact inhibition of GSK3 has 
been found to promote and maintain mESC self-renewal 
[23]. As shown in Figure 3, in the majority of the cases 
normalization against protein level revealed no protein 
level change modulating stoichiometry of phosphorylation. 
For example, Hmga2 expression was augmented as ES 
cells differentiate and it remains high in the Bry+Flk1+: we 
found a peptide whose phosphorylation increased as mES 
cells differentiate, and this phosphorylation is maintained 
in the Bry+Flk1+ population. Hmga2 can exert a negative 
regulation on the Jak-Stat signaling cascade [24]. The 
Jak/Stat pathway promotes ESCs self-renewal [25] and 
is required for self-renewal of Drosophila sperm stem 
cells [26]. Conversely, only few phosphopeptides did not 
exhibit a correspondence between phosphorylation and 
protein expression. Among these, is the phosphopeptide 
emanating from the chromatin remodeling factor Smarcc1/
Baf155, whose phosphorylation increased as mESCs 
differentiated toward mesoderm lineage commitment. 
Interestingly, Schaniel et co-workers [27], showed that 
Smarcc1 plays a balance between gene repression, which 
maintains ESCs in the self-renewal state and chromatin 
rearrangements, that led to the expression of genes 
involved in differentiation.
DISCUSSION
Phosphoproteomic data can be a powerful tool to 
broaden understand of ES cells and how their ultimate 
fate is determined. Many transcription regulators such 
as epigenetic and transcription factors, as well as a large 
number of kinases are phosphorylated in embryonic stem 
cells [18–28, 29], suggesting that these post-translational 
modifications play a key role in determining stem cell 
fate. Our study reported the identification of novel 
phosphosites within proteins involved in ES cell mesoderm 
differentiation and the relative quantification of the 
phosphorylation stoichiometry during the progression from 
epiblast-like cells to the hemangioblast (BL-CFC cells).
The Gene Ontology classification highlighted 
that different biological processes play a role during 
the mesoderm-induced mESCs differentiation. During 
differentiation, phosphopeptides emanated from proteins 
involved in embryonic development were identified. 
In the last stage, when the hemangioblast is formed, 
phosphorylation differentially influences proteins 
involved in cell cycle, regulation of transcription and 
signaling pathways, indicating that mass spectrometry 
and phosphoproteomic analysis identified key modulators 
of the development process toward blood. For example, 
we reported a phosphopeptide emanated from Uhrf1 
(also called Np95), which is known to contain a cyclin 
A/E-Cdk2 phosphorylation site. It has been demonstrated 
not only that Uhrf1 is essential for maintaining genomic 
methylation in embryonic stem cells by recruiting 
DNA methyltransferase (Dnmt) 1 to hemi-methylated 
CpG sites generated during replication [30], but also to 
interact with de novo methyltransferases Dnmt3a and 
Dnmt3b, mediating promoter silencing before DNA 
methylation is detected [31]. Uhtf1 is also involved in 
the regulation of Top2a. It has been suggested that Uhrf1 
regulates transcription of Top2a by binding to an inverted 
5′-CCAAT-3′ box in the Top2a promoter and activating 
expression [32]. Moreover it has been established that 
Uhfr1 contributes to genomic stability functioning in the 
response pathways against DNA damage and replication 
arrest [33]. Phosphopeptides emanated from both Top2a 
and Dnmt3b were found within our dataset.
Of particular interest was the identification 
of a phosphopeptide emanated from GSK3b, which 
phosphorylation increases as stem cells differentiate. GSK3b 
activity has been demonstrated to be crucial for the switch 
between stem cell self-renewal and differentiation. The 
regulation of GSK3 activity is able to inhibit self-renewal 
and promote differentiation [34]. But GSK3 functions in a 
wide range of cellular processes and it can both act as a tumor 
suppressor and as oncogene, in the development of various 
human cancers [35–37]. Of the phosphopetide emanated 
proteins within our dataset, 7 proteins present with at least 1 
potential site that can be phosphorylated by GSK3b with high 
stringency (http://scansite3.mit.edu) (Acin1, Blacf1, Dnmt3b, 
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Figure 3: Comparison between phosphopeptides and protein expression levels. Panels show changes in identified 
phosphopeptides compared to the expression profile of the referring proteins previously identified [4]. Blue histograms represent 
phosphorylation and orange histograms refer to protein expression level changes in Bry–Flk1– (Epiblast-like cells), Bry+Flk1– (Early 
mesoderm) and Bry+Flk1+ (Hemangioblast).
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Pnn, Rif1, Srrm2, Thrap3). Only 1 of the phosphopeptides 
identified contain the putative GSK3b consensus sequence 
(Abi1, medium stringency).
Another interesting protein was the Smarcc1/
Baf155, that we found to be phosphorylated on S327 and 
S329; the phosphorylation of this doubly phosphorylated 
peptide decreased as stem cells differentiate toward 
the mesoderm commitment. Smarcc1/Baf155 belongs 
to the SWI/SNF multiprotein chromatin remodeling 
complex, and is required for heterochromatin formation 
and chromatin condensation during differentiation. In 
human ES cells, Smarcc1/Baf155 plays a dual role in 
maintaining pluripotency: it can promote or repress self-
renewal gene expression, e.g. Nanog [38]. Furthermore, 
the SWI/SNF chromatin-remodeling complex also 
promotes somatic cell reprogramming by facilitating 
Oct4 binding to its target promoters. In retinoic acid-
mediated differentiation, Baf155 can integrate p53 
function to regulate ectodermal and mesodermal gene 
expression [27]. The possibility of Aurka-mediated p53 
phosphorylation altering the interaction between p53 
and the SWI/SNF complex as well as other epigenetic 
regulatory complexes is particularly tantalizing and may, 
in part, explain the apparent paradoxical requirement for 
SWI/SNF in both ESC maintenance and differentiation. As 
in silico analysis suggests (http://scansite3.mit.edu), Erk1 
might be the kinase deputated to phosphorylate S327 and 
S329. Recently, Erk1/2, as GSK3b, was found to promote 
self-renewal, maintaining cellular growth capacity and 
reinforcing suppression of commitment [39–40].
We are only beginning to understand the molecular 
and cellular mechanisms of normal hematopoietic 
development and many pieces of these puzzle are still 
missing. The in vitro differentiation of ES cells has been 
instrumental in the identification and characterization of 
the hemangioblast.
Understanding how blood cells are generated is 
important from a biological perspective but also has 
potential implications in the treatment of blood diseases. 
Searches for post-translational regulatory processes 
are likely to lead to the identification of new important 
players in blood specification than can be altered in blood 
cancers. Knowing how signaling molecules regulates, by 
phosphorylation, their downstream targets could represent 
a precise stem cell signaling process that can lead to blood 
cancers, if unregulated or disrupted.
MATERIALS AND METHODS
Cell culture and differentiation
The Bry+ ES cell line was generated by Fehling et 
al. [3], introducing the GFP gene into one allele of the Bry 
(Brachyury) gene of the mouse embryonic stem cell line 
clone E14.1. ES cells were maintained and differentiated 
as previously described [3].
Cell sorting flow cytometry
EBs were harvested, trypsinized and the single cell 
suspension analyzed on a FacsCalibur flow cytometer (BD 
Bioscences). Staining and isolation of cell populations were 
performed as previously described [3]. The expression of 
Bry with the Flk1 receptor in a temporal pattern revealed 
the emergence of three distinct populations, Bry–Flk1–, 
Bry+Flk1–, Bry+Flk1+, which represented a developmental 
progression from epiblast-like to early mesoderm then 
BL-CFC cells [3]. These sorted populations were used for 
analysis of the phosphoproteome.
Nuclear isolation
Nuclear extraction was performed using the 
Nuclear Extract kit (Active Motif, Brussels, Belgium) as 
previously described [41]. Briefly, 1x107 cells from each 
sorted population were washed in ice cold Hanks buffer 
(136.7 mM NaCl, 5.35 mM KCl, 0.812 mM MgSO
4
, 1.28 
mM CaCl
2
, 5.5 mM Glucose, 24 mM Hepes, pH 7.4) with 
phosphatase inhibitors and then lysed in hypotonic buffer, 
following the manufacturer’s instructions. Nuclei were 
then lysed in 1 M triethylammonium bicarbonate lysis 
buffer (TEAB, Sigma-Aldrich, St. Louis, MO), 0.05% 
(w/v) SDS, protease inhibitor cocktail, phosphatase 
inhibitors and Benzonase (Novagen, UK). The protein 
concentration was determined using the Bradford protein 
assay (Bio-Rad, Hemel Hempstead, UK). The nuclear 
purity was assessed by Western Blot analysis for nuclear 
(lamin a/c) and cytoplasmic (β-tubulin) markers.
4-plex iTRAQTM labeling
An aliquot of 100 μg of each nuclear protein sample 
was reduced, digested and labeled with four-channel 
iTRAQTM reagent (Applied Biosystem, Framingham, 
MA) according with the manufacturer’s instructions. As 
previously described [41], protein were reduced with 50 
mM tris-(2-carboxyethyl)phosphine, then alkylated by 
adding 200 mM methylmethanethiosulphate. Trypsin 
(5 μg, 0.5 μg/μl, Promega) was added, and the samples 
were incubated overnight at 37°C. After cooling to 
room temperature, peptides were dried, reconstituted 
in 20 μl TEAB and labeled with iTRAQTM reagent. In 
all experiments isobaric labeling exceeded 99% of total 
identified peptide using mass spectrometry. The four 
isobarically labeled reactions were pooled together and 
dried down.
TiO
2
 phospho-enrichment
The iTRAQTM labeled peptide mixture was 
resuspended in 150 μl of lactate loading buffer (240 mg/
ml lactate in 80% (v/v) Acetonitrile, 1% (v/v) Trifluoro-
acetic acid (TFA). TiO
2
 columns (TopTip, Glygen, Corp, 
USA) were equilibrated with 150 μl of lactate loading 
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buffer then the samples loaded. The tip was washed twice 
with 60 μl of lactate loading buffer and four times with 60 
μl of wash buffer (80% (v/v) Acetonitrile, 5% (v/v) TFA). 
Bound peptides were then recovered by elution in 60 μl 
of elution buffer (ammonium water [20 μl NH
3
 in 980 μl 
H
2
O], pH 10.5). samples were then concentrated to a few 
μl in a SpeedVac prior to Strong Cation Exchange (SCX) 
chromatography.
SCX fractionation
Enriched phosphopeptides were fractionated off-
line using an SCX cation exchange column (10 cm × 2.1 
mm PolyLCPolysulfoethyl A column, 5 μm beads, 200 μÅ 
pore size (The Nest Group, Southborough, MA, USA) on 
a LC Packings Ultimate LC system running at 250 μl/min. 
Peptides were diluted 10-fold in SCX loading buffer (10 
mM KH
2
PO
4
 in 25% (v/v) ACN, pH 2.7). The eluate was 
collected in 1 min intervals over the following gradient 
of increasing salt concentration: a 45 min linear gradient 
of 0–250 mM KCl, followed by a 10 min linear gradient 
of 250–500 mM KCl, then 5 min of 1 M KCl. Each 
fraction was then lyophilized in a SpeedVac concentrator 
(Labconco).
Mass spectrometry
Peptides were analyzed using a QStar® XL mass 
spectrometer (AB Sciex, Warrington, UK) as previously 
described [41]. Briefly, dried peptide fractions were 
resuspended in 120 μl of Buffer A (2% (v/v) acetonitrile 
0.1% (v/v) formic acid). For each analysis 60 μl of 
sample was loaded onto a on-line column (15 length;75 
μm inner diameter) packed with RP C
18
 PepMap100 
(3 μm, 100 A) using a Ultimate pump (LC Packings, 
Amsterdam, Netherlands) and separated over a 120 min 
solvent gradient from 5.9% (v/v) acetonitrile/0.1% (v/v) 
formic acid to 41% (v/v) acetonitrile/0.1% (v/v) formic 
acid coupled to a QStar® XL mass spectrometer (AB 
Sciex, Warrington, UK). Data were acquired using an 
information dependent acquisition (IDA) designed with 
Analyst QS 2.0 (AB Sciex, Warrington, UK) where, for 
each cycle, the two most abundant multiply charged 
peptides (2+ to 4+) above a 20 count threshold in the 
MS scan with m/z between 400 and 2000 were selected 
for MS/MS. Each ion was selected a maximum of two 
times, and then dynamically excluded (± 50 mmu) for 
40 seconds.
Data analysis
Spectra were processed using ProteinPilotTM 
v.3 software (Paragon algorithm v.3.0.0.0, AB Sciex, 
Warrington, UK), searching against a mouse Celera 
Discovery System database (mouse_KBMS5_0_20050302, 
115.660 entries). Default search parameters were set with 
MS tolerance of 0.5 Da, MS/MS tolerance of 0.1 Da. 
Identification focus was on biological modifications with 
phosphorylation emphasis as a special factor. Search 
parameters include methylmethanethiosulfonate (MMTS) 
alkylation of cysteine, iTRAQTM modification of lysine 
and N-terminal residues. The searched parameter was set 
for reverse searching for false discovery, so that at the 
95% confidence level there is a false positive identification 
rate of < 1%. Ratio values for each phosphoentity were 
obtained from weighted averages of multiple spectra 
when appropriate, similarly to the way ProteinPilotTM 
calculates ratios for proteins. Phosphopeptides identified 
with a confidence ≥ 20 were included in the analysis. 
ProteinPilotTM biases were used to correct for any 
sampling error so that the median value of log2(ratios) of 
the phosphoentity distribution is equal to 0 for each pair 
of iTRAQTM reagents. The distribution of the biological 
replicates Control(Bry-Flk-):Control(Bry-Flk-) was used 
to determine the biological variability of the procedure 
by combining the 2 control ratios. Student’s t test was 
performed between the values of 2 biological replicates for 
each appropriate ratio and the Gaussian distribution of the 
biological replicates. Phosphoentities with a Student’s t-test 
p value < 0.05 were considered as potentially changing. 
Phosphoentities changing between the controls, i.e. for Bry-
Flk-:Bry-Flk- ratio, with a p value < 0.05 were manually 
removed from the analysis. All the phosphorylation events 
were validated manually using the spectral data acquired. 
The phospho-dataset was then compared with the dataset 
obtained from the total nuclear expression analysis [4].
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